ライフサイエンスコーパス: psychotropic

1 morbidity was associated with greater use of psychotropics.

2 beta blockers, calcium channel blockers, or psychotropics.

3 c and anti-inflammatory activity without the psychotropic action of THC.

4 her experimental studies to understand their psychotropic action.

5 finding that salvinorin A exerts its potent psychotropic actions through the activation of opioid re

6 cid diethylamide are thought to elicit their psychotropic actions via serotonin receptors of the 5-hy

7 ine has important anesthetic, analgesic, and psychotropic actions.

8 ins such as ergot alkaloids that have potent psychotropic activity.

9 noid levels and action, which exhibit little psychotropic activity.

10 s (13 trials), prokinetic agents (6 trials), psychotropic agents (7 trials), and loperamide (4 trials

11 otics (n=22), antidepressants (n=202), or no psychotropic agents (n=85).

12 Psychotropic agents act on a variety of neurotransmitter

13 hough safety and efficacy of the use of many psychotropic agents in children remain largely unproved,

14 Ethanol is one of the most widespread psychotropic agents in western society.

15 Evidence for use of psychotropic agents is inconclusive; more high-quality t

16 not increased when patients were assigned to psychotropic agents rather than placebo except for heter

17 s can potentially interact with a variety of psychotropic agents via cytochrome P450 and p-glycoprote

18 Although psychotropic agents were shown to produce global improve

19 The role of psychotropic agents, especially tricyclic antidepressant

20 urthermore, 3- to 4-month exposure to modern psychotropic agents, such as atypical antipsychotic agen

21 gs, notably clozapine, as well as some other psychotropic agents.

22 ive hepatitis C status who were taking other psychotropic agents.

23 receptors may have therapeutic potential as psychotropic agents.

24 of the endogenous counterpart of marijuana's psychotropic and appetite-inducing component Delta(9)-te

25 cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millenni

26 etabolites may prolong the parent compound's psychotropic and physiological effects and may contribut

27 etabolites may prolong the parent compound's psychotropic and physiological effects and may contribut

28 nt pain therapeutics suffer from undesirable psychotropic and sedative side effects, as well as abuse

29 ccurrence of Salmonella, Escherichia coli or psychotropic bacteria.

30 ychoactive constituent of marijuana, and the psychotropic cannabinoid (-)Delta9-tetrahydrocannabinol

31 nce exists to support the use of alternative psychotropic classes (e.g., antidepressants, anticonvuls

32 The main psychotropic component in marijuana, Delta(9)-tetrahydro

33 brain elimination half-life for fluorinated psychotropic compounds can be measured noninvasively by

34 acute 20-min exposure to two commonly abused psychotropic compounds, Delta(9)-tetrahydrocannabinol (T

35 , and that the neuroprotective effect of the psychotropic Delta9-tetrahydroxycannabinol (THC) or nonp

36 ase in the proportion of existing users with psychotropic dose increases in the weeks after the attac

37 nes may influence phenotypes associated with psychotropic drug administration.

38 Psychotropic drug costs increased during the first year

39 the potentially confounding effects of prior psychotropic drug exposure.

40 had not received any sedation, narcotic, or psychotropic drug in the previous 24 hrs.

41 -HT(2C) receptors in motivated behaviors and psychotropic drug mechanisms.

42 Using this approach, we identified the psychotropic drug pimozide as a STAT5 inhibitor.

43 ent with lamotrigine was initiated and other psychotropic drug regimens were discontinued, patients w

44 pect of identifying biological predictors of psychotropic drug response and could provide the means o

45 nitial research into the pharmacogenetics of psychotropic drug response suggests that specific genes

46 rst generation of pharmacogenetic studies of psychotropic drug response, and consider future directio

47 el method of dissecting the heterogeneity of psychotropic drug response.

48 rovides a mechanism of adaptation to chronic psychotropic drug treatment.

49 ncluding chronic electroconvulsive seizures, psychotropic drug treatments, and lesions.

50 Although sex differences occur with some psychotropic drug treatments, they are not well defined

51 bid personality disorder (1.24 [1.11-1.39]), psychotropic drug use (antipsychotics 1.51 [1.35-1.69],

52 Psychotropic drug use was lower among African Americans

53 parents' report of neurologic complications, psychotropic drug use, and special education.

54 nmental and personal safety, wheelchair use, psychotropic drug use, and transferring and ambulation.

55 rgest category, decreased as a proportion of psychotropic drug visits (P< or =.01) and are now surpas

56 Surprisingly, another psychotropic drug, phencyclidine, displayed a selective

57 ripheral OE can serve as a proxy for certain psychotropic drug-induced actions on SVZ brain cell prol

58 These results show that psychotropic drug-induced cell proliferation occurs in t

59 sonance imaging studies were conducted in 21 psychotropic drug-naive children, aged 8 to 17 years, wi

60 n severity on the CY-BOCS in the subgroup of psychotropic drug-naive patients.

61 MRI examinations of 37 psychotropic drug-naive pediatric OCD patients and 26 ag

62 ous 1.5-mm magnetic resonance images from 23 psychotropic drug-naive pediatric patients with OCD (sev

63 ry to examine brain structure, especially in psychotropic drug-naive pediatric patients.

64 ents with current insomnia, 28% received any psychotropic drug; 14% received benzodiazepines and 19%

65 chronic administration of nonantidepressant psychotropic drugs (cocaine or haloperidol), demonstrati

66 e, and stress, repeated treatment with other psychotropic drugs (haloperidol, raclopride, sertraline,

67 e of cimetidine (OR 2.5, 95% CI 1.4-4.6) and psychotropic drugs (OR 2.2, 95% CI 1.4-3.3).

68 re (OR, 4.99; 95% CI, 1.16 to 21.38) or with psychotropic drugs (OR, 2.78; 95% CI, 1.10 to 7.01).

69 tric outpatients taking weight gain-inducing psychotropic drugs (sample 1, n = 152).

70 e intracellular chaperone proteins that bind psychotropic drugs and also clinically used drugs such a

71 ard and dependence, brain trauma and injury, psychotropic drugs and pain using small animals.

72 of therapies should be used, and the use of psychotropic drugs and psychological treatment alternati

73 ectrocardiogram in pediatric patients taking psychotropic drugs and recommendations for monitoring th

74 widely; they bind diverse ligands, including psychotropic drugs and steroids, regulate many ion chann

75 ng in zebrafish to discover and characterize psychotropic drugs and to dissect the pharmacology of co

76 Treatment patterns for psychotropic drugs appear to have remained stable over t

77 pensity substantially increase when specific psychotropic drugs are administered to patients with hyp

78 The authors examined how the use of psychotropic drugs has shifted over the course of 10 yea

79 Many specific psychotropic drugs have been reported to prolong the QTc

80 Therapeutic outcomes from several psychotropic drugs have been weakly linked to specific g

81 death in pediatric patients taking selected psychotropic drugs have raised the possibility of ventri

82 The use of psychotropic drugs in clinical and translational brain r

83 The use of psychotropic drugs in the pediatric population has incre

84 yping and screening of genetic mutations and psychotropic drugs in zebrafish (Danio rerio).

85 Many psychotropic drugs interfere with the reuptake of dopami

86 , address this question and demonstrate that psychotropic drugs modify specific methyl-CpG-binding pr

87 -blind, placebo-controlled trial (Effects of Psychotropic Drugs on Developing Brain-Methylphenidate)

88 ch more likely to receive a variety of other psychotropic drugs than nonusers of the same sex and age

89 t mediates the modulation of ion channels by psychotropic drugs through a unique transduction mechani

90 atient care was 4.2%, and for treatment with psychotropic drugs was 32.3%.

91 The major classes of psychotropic drugs were introduced in an extraordinary d

92 77 [95% CI, 1.72 to 4.44] for treatment with psychotropic drugs).

93 Psychotropic drugs, 5-hydroxytryptamine (5-HT)-receptor

94 hildren with OCD who had not been exposed to psychotropic drugs, aged 7 to 18 years, and 19 case-matc

95 hat bind certain steroids, neuroleptics, and psychotropic drugs, form a trimeric complex with ankyrin

96 g-term adaptations underlying the effects of psychotropic drugs, including the actions of antidepress

97 ric conditions, and concomitant use of other psychotropic drugs, risk of suicide death was 2.7 times

98 Under the influence of commonly used psychotropic drugs, some acutely ill, hospitalized patie

99 cognition, and addiction and is regulated by psychotropic drugs, stress, and corticosteroids.

100 Use of psychotropic drugs, use of mental health services, and d

101 protein (CREB) in the adaptive responses to psychotropic drugs, we have developed inducible, brain r

102 peutic actions as well as adverse effects of psychotropic drugs.

103 ar dysrhythmias in pediatric patients taking psychotropic drugs.

104 chiatric patients and the effects of various psychotropic drugs.

105 rcent of the patients were also treated with psychotropic drugs.

106 ad substitution of antipsychotics with other psychotropic drugs.

107 -tetrahydrocannabivarin, which are devoid of psychotropic effects and possess potent anti-inflammator

108 Endocannabinoid (EC) signaling mediates psychotropic effects and regulates appetite.

109 HU-320 administration yielded no adverse psychotropic effects in mice.

110 The psychotropic effects of Delta9-THC may result from inhib

111 ratory behavior and suggest that some of the psychotropic effects of LSD may be mediated by 5-HT5A re

112 tes have been suggested to contribute to the psychotropic effects of the cannabinoids; however, the m

113 primary and secondary mood disorders and the psychotropic effects of thyroid axis manipulations.

114 rious pathologies while avoiding the adverse psychotropic effects that can accompany CB1 receptor-bas

115 of biological effects ranging from transient psychotropic effects to prolonged medicinal benefits, ma

116 ng cannabinoid agonists are known to produce psychotropic effects, it has been suggested that the CB1

117 Also, because CB2 agonists lack psychotropic effects, they may serve as novel anticancer

118 a is one of the most abused drugs due to its psychotropic effects.

119 cretion on mood regulation and the potential psychotropic efficacy of androgen replacement in men are

120 exposure, compared with antidepressant or no psychotropic exposure, was associated with significantly

121 nd decrease the plasma concentration of many psychotropic, immunosuppressant, antineoplastic, antimic

122 Use of psychotropics in general, and antidepressants in particu

123 Subjects consisted of 68 psychotropic (including stimulant)-naive and smoking-nai

124 tions (opioid pain medications and nonopioid psychotropics, including antidepressants/anxiolytics and

125 k relative to no treatment or an alternative psychotropic is unclear.

126 those with antidepressant (mean=68.57) or no psychotropic (mean=71.19) exposure, after controlling fo

127 oms were more likely to have been prescribed psychotropic medication (adjusted odds ratio = 1.9; 95%,

128 nary frequency or leaking (P = .006), use of psychotropic medication (P = .009), and denial of life a

129 s before the cancer death/index date, use of psychotropic medication 6 months before the cancer death

130 ehavior disorders as well as nonadherence to psychotropic medication and lower socioeconomic levels.

131 Use of psychotropic medication and presence of comorbid major d

132 both relative to patients not receiving any psychotropic medication and relative to their pretreatme

133 effect persisted after covarying for current psychotropic medication and severity of current depressi

134 ated the relative mortality, prescription of psychotropic medication and use of primary medical care

135 Abrupt discontinuation of long-term psychotropic medication can be followed by a high risk o

136 ecently diagnosed OCD who had never received psychotropic medication demonstrated no cognitive impair

137 sions to terminate a pregnancy if prescribed psychotropic medication during early pregnancy than if n

138 otic symptoms (47.6%) had taken a prescribed psychotropic medication during the last month.

139 onth), 4.1% of whom had a prescription for a psychotropic medication during the study period.

140 Psychotropic medication exposure has been shown to alter

141 dedness-, and education-matched HCs, free of psychotropic medication for at least 12 weeks, viewed 60

142 All subjects had been free of psychotropic medication for at least 4 weeks.

143 The data supporting concomitant psychotropic medication for youths are almost exclusivel

144 dentify available information on concomitant psychotropic medication for youths.

145 o the prevalence and patterns of concomitant psychotropic medication given to youths with emotional a

146 elements of detailed first-episode-specific psychotropic medication guidelines and a computerized de

147 % reported that they had been treated with a psychotropic medication in the past 12 months.

148 harmacodynamics, and side-effect profiles of psychotropic medication in this population.

149 95% CI=0.59-0.90) declined while use of only psychotropic medication increased (44.1% and 57.4%; adju

150 ctual disability have behaviour problems and psychotropic medication is a commonly used management st

151 g disorder; in the case of anorexia nervosa, psychotropic medication is generally reserved for patien

152 When psychotropic medication is used during breast-feeding, i

153 but few studies, that examine the effect of psychotropic medication on anxiety disorders in children

154 Psychotropic medication polypharmacy is common in psychi

155 3 months, falls, fall-related fractures, and psychotropic medication prescriptions.

156 rences in falls, fall-related fractures, and psychotropic medication prescriptions.

157 36 healthy control (HC) participants free of psychotropic medication recruited from several psychiatr

158 % CI=0.48-0.90) as well as psychotherapy and psychotropic medication together (40.0% and 32.1%; adjus

159 )) locus (HTR2A), previously associated with psychotropic medication treatment outcome.

160 t a major issue is the potential confound of psychotropic medication upon experimental measures.

161 telligence quotient and after accounting for psychotropic medication usage and comorbid psychopatholo

162 This study examined patterns of psychotropic medication use after the Sept. 11, 2001, te

163 Depression and psychotropic medication use are potential risk indicator

164 y mental disorders during the 3 prior years, psychotropic medication use during the prior year, and i

165 ffects on decreasing behavioral symptoms and psychotropic medication use in dementia residents in lon

166 The patterns of psychotropic medication use in outpatient medical practi

167 Psychotropic medication use in the past 12 months.

168 episode, dysphoria (2 weeks of sadness), and psychotropic medication use were assessed in 1981, and s

169 mine the association of mental disorders and psychotropic medication use with osteoporotic fracture r

170 for major depressive disorder, were free of psychotropic medication use, and had a baseline 17-item

171 over time by provider specialty, concomitant psychotropic medication use, number of annual visits, an

172 ore rapidly and has coincided with increased psychotropic medication use.

173 Psychotropic medication visits increased at comparable r

174 The number of visits during which a psychotropic medication was prescribed increased from 32

175 ortion of mental health outpatients received psychotropic medication without psychotherapy.

176 human resources, rehabilitation facilities, psychotropic medication, and community mental health as

177 duration of inpatient admissions, the use of psychotropic medication, and self-report measures of dep

178 rimary care physicians prescribe concomitant psychotropic medication, and they show great variability

179 using mental health services (talk therapy, psychotropic medication, and/or a support group), most c

180 diagnosis of MDD, not currently treated with psychotropic medication, between ages of 18 and 65 (mean

181 ng participants who did not voluntarily take psychotropic medication, even minor assaultiveness was a

182 lth conditions with only psychotherapy, only psychotropic medication, or their combination; the mean

183 c treatment lasted 6 months and consisted of psychotropic medication, psychoeducation, and brief supp

184 a clinical research facility completed by 75 psychotropic medication-free patients with remitted MDD

185 Oculomotor tests were administered to 18 psychotropic medication-naive, nondepressed patients wit

186 ic disorder, current depression, and current psychotropic medication.

187 n antipsychotic drug treatment with a second psychotropic medication.

188 None was taking psychotropic medication.

189 tment are most likely to receive concomitant psychotropic medication.

190 sychiatric facilities were given concomitant psychotropic medication.

191 nces were found in patients currently taking psychotropic medication.

192 ents, and patients who were not prescribed a psychotropic medication.

193 re not depressed, and none had ever received psychotropic medication.

194 present whether or not the participant takes psychotropic medication.

195 e the likelihood of off-label prescribing of psychotropic medication.

196 pression is associated with being prescribed psychotropic medication.

197 Outpatient mental health treatment and psychotropic-medication use in children and adolescents

198 der (22.5% vs 5.8%; P = .005), and receiving psychotropic medications (18.0% vs 4.7%; P = .007), intr

199 ds with or without dispensed prescription of psychotropic medications (antipsychotics, antidepressant

200 use of psychotherapy (from 4.2% to 6.0%) and psychotropic medications (from 5.5% to 8.9%), including

201 health diagnoses (P = 0.019) and the use of psychotropic medications (P = 0.015) were significantly

202 e of the most commonly prescribed classes of psychotropic medications among US youths.

203 -SSRI antidepressants, and nonantidepressant psychotropic medications and analyses in the clinically

204 riod of expansion in the number of available psychotropic medications and growth in managed behaviora

205 Before treatment, all subjects were free of psychotropic medications and had a score </=20 on the Ce

206 Maintenance psychotropic medications and supportive psychotherapy we

207 te the associations between major classes of psychotropic medications and violent reoffending.

208 Psychotropic medications are widely prescribed, but how

209 , most patients in these studies were taking psychotropic medications at the time of PPI testing, and

210 scribes the prevalence and pattern of use of psychotropic medications by HIV-positive patients receiv

211 U.S. prescriptions (156.9 million claims for psychotropic medications during the study period) and a

212 Recent reports on the use of psychotropic medications for preschool-aged children wit

213 Although mortality related to psychotropic medications has received much attention in

214 re widely prescribed, but how new classes of psychotropic medications have affected prescribing patte

215 Many other psychotropic medications have been considered and used t

216 stimated 27.2% of HIV-positive patients took psychotropic medications in 1996.

217 e 1955 was conducted to determine the use of psychotropic medications in breast-feeding women.

218 No controlled studies on the safety of psychotropic medications in nursing mothers were found.

219 over widespread overmedication and misuse of psychotropic medications in US youth.

220 Combining psychotropic medications is common for people diagnosed

221 Rapid discontinuation of some psychotropic medications is followed by discontinuation

222 Finally, the use of psychotropic medications is not unusual in personality d

223 Numerous other psychotropic medications may be considered, alone or in

224 Treatment with psychotropic medications may contribute to obesity in wa

225 Many psychotropic medications must be considered when treatin

226 ignificant effect or ameliorative effects of psychotropic medications on abnormal structural and func

227 linical studies have demonstrated effects of psychotropic medications on PPI.

228 er Lhx6 mRNA levels were not attributable to psychotropic medications or illness chronicity.

229 These differences were not attributable to psychotropic medications or other comorbid factors.

230 There was an increase in the number of psychotropic medications prescribed across years; visits

231 In all 3 data sources, psychotropic medications prescribed for preschoolers inc

232 compared NAVIGATE and community care on the psychotropic medications prescribed, side effects experi

233 small case series for each of the different psychotropic medications serve as the basis for suggeste

234 Most of the evidence on other psychotropic medications such as antidepressants, mood s

235 Psychotropic medications target glycogen synthase kinase

236 Diagnostic Interview and a questionnaire on psychotropic medications used during the previous 6 mont

237 nd adjusted costs for services and dispensed psychotropic medications were calculated.

238 Psychotropic medications were discontinued before random

239 6 months, and who were free of hormonal and psychotropic medications were recruited into 4 study gro

240 ntly face the need to decide whether to take psychotropic medications while breast-feeding.

241 essant without a clear indication, 10.1% for psychotropic medications without an antipsychotic, and 1

242 total brain volume, age, gender, education, psychotropic medications, alcohol use, and race/ethnicit

243 er involvement of physicians, greater use of psychotropic medications, and expanding availability of

244 12-month mental disorder had been prescribed psychotropic medications, and most had evidence of psych

245 otic or manic symptoms, no use of concurrent psychotropic medications, and no current dependence on i

246 f comorbid major depressive disorder, use of psychotropic medications, assay used, and time of day bl

247 Despite evidence of the increasing use of psychotropic medications, little is known about the broa

248 All subjects were free of alcohol, psychotropic medications, or drugs of abuse.

249 ases in the use of and costs associated with psychotropic medications, particularly for youths with m

250 n mental disorder diagnoses, prescription of psychotropic medications, provision of psychotherapy, or

251 ht also exhibit changes after treatment with psychotropic medications.

252 nstrated following administration of several psychotropic medications.

253 ation services, neurologic events, or use of psychotropic medications.

254 ithout mental disorders and those not taking psychotropic medications.

255 were not using any mental health services or psychotropic medications.

256 of individuals with dose increases in their psychotropic medications.

257 ied by a commensurate increase in the use of psychotropic medications.

258 tions, new prescriptions, or daily doses for psychotropic medications.

259 actures based on mental disorders and use of psychotropic medications.

260 and increased public acceptance of effective psychotropic medications.

261 e course of 10 years to examine their use of psychotropic medications.

262 treatment for weight gain in patients taking psychotropic medications.

263 physicians and provided in conjunction with psychotropic medications.

264 milar regions of the brain, or the effect of psychotropic medications.

265 articipants were weight-restored and free of psychotropic medications.

266 K3beta activity contributes to the action of psychotropic medications.

267 pulation or among control groups using other psychotropic medications.

268 antidepressants, or other nonantidepressant psychotropic medications.

269 Adjustments were made for other psychotropic medications.

270 health systems might improve availability of psychotropic medicines and that overall country developm

271 While access to psychotropic medicines varies substantially across count

272 Availability of psychotropic medicines was associated with features of a

273 e interventions, including administration of psychotropic medicines, the number of persons who remain

274 systems components associated with access to psychotropic medicines.

275 an produce proteases: among them, those from psychotropic microorganisms (e.g. Bacillus subtilis), wh

276 etylhomotaurinate by itself is not an active psychotropic molecule.

277 al profiling revealed conserved functions of psychotropic molecules and predicted the mechanisms of a

278 le in animal models of FXS and assessment of psychotropic monotherapy on ERK activation.

279 dies have examined frontostriatal anatomy in psychotropic-naive children with OCD near the onset of i

280 sonance imaging studies were conducted in 22 psychotropic-naive patients with MDD, aged 9 to 17 years

281 od or adolescence, few studies have examined psychotropic-naive pediatric patients near the onset of

282 functioning, and unanswered questions about psychotropic or protease inhibitor drug interactions due

283 related to depression symptoms, medications (psychotropics), or failure to perceive/appreciate the ne

284 aapi is the basic ingredient of ayahuasca, a psychotropic plant tea used in the Amazon for ritual and

285 receptors serve as molecular targets for the psychotropic plant-derived cannabis constituent Delta(9)

286 The increasing trend of psychotropic polypharmacy was mostly similar across visi

287 e analyzed to examine patterns and trends in psychotropic polypharmacy within nationally representati

288 in 2004 and 2009 on antipsychotic and other psychotropic prescribing.

289 er adjustment for age, gender, number of non-psychotropic prescriptions 6 months before the cancer de

290 ization (e.g., medication management visits, psychotropic prescriptions, and mental health/substance

291 t no significant increase in the rate of new psychotropic prescriptions.

292 ple) who might benefit from changes in their psychotropic prescriptions.

293 y should not cross the BBB to avoid possible psychotropic side effects.

294 ated by the need to avoid cardiovascular and psychotropic side effects.

295 Exclusion criteria were the use of illicit psychotropic substances, mental confusion, hepatic encep

296 Psychotropic treatment has been frequently associated wi

297 Psychotropic treatments included antipsychotics for schi

298 ges in CRMPs levels have been observed after psychotropic treatments, and disrupting CRMP2 binding to

299 We observed disparities in nonopioid psychotropic use between black and white women (adjusted

300 Psychotropics were commonly used by HIV-positive patient